



# Analysis of Apoptosis Methods Recently Used in Cancer Research and Cell Death & Disease Publications

## Citation

Bucur, Octavian, A. L. Stancu, Roya Khosravi-Far, and A. Almasan. 2012. Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. *Cell Death & Disease* 3(2): e263.

## Published version

<https://doi.org/10.1038/cddis.2012.2>

## Link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:8519647>

## Terms of use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at

<https://harvardwiki.atlassian.net/wiki/external/NGY5NDE4ZjgzNTc5NDQzMGIzZWZhMGFIOWI2M2EwYTg>

## Accessibility

<https://accessibility.huit.harvard.edu/digital-accessibility-policy>

## Share Your Story

The Harvard community has made this article openly available.  
Please share how this access benefits you. [Submit a story](#)

## Editorial

# Analysis of apoptosis methods recently used in *Cancer Research* and *Cell Death & Disease* publications

O Bucur<sup>1,2,5</sup>, AL Stancu<sup>1,3,5</sup>, R Khosravi-Far<sup>\*,1</sup>, A Almasan<sup>\*,4</sup>

*Cell Death and Disease* (2012) 3, e263; doi:10.1038/cddis.2012.2; published online 2 February 2012

Over several decades, significant advances have been made in implementing several morphological and biochemical criteria to define and characterize apoptosis. In order to appropriately identify apoptosis in cellular cultures or *in vivo* (animal models), with the ultimate aim of discovering novel, useful, specific, and powerful pro-apoptotic antitumoral drugs, it is necessary to accurately validate apoptotic processes through morphological, biochemical, or immunological methods.

Often, apoptosis is detected and/or measured by only one method and the authors frequently use imprecise terminology, such as ‘% apoptosis’, ‘% cell death’, instead of defining the specific method used such as ‘% cells with condensed chromatin’, ‘% cells TUNEL positive’, ‘% cells Annexin V positive’ and others.<sup>1</sup> The Nomenclature Committee on Cell Death (NCCD) recommends and encourages researchers to demonstrate that apoptosis or other forms of cell death take place using more than one assay, as an artifact removal feature, and to avoid the ‘confusing and imprecise’ nomenclature, such as ‘% apoptosis’, which ‘should definitively be abandoned’.<sup>1</sup> Moreover, the NCCD ‘urges’ all life science journals to join the *Cell Death and Differentiation* journal in adopting these recommendations.<sup>1</sup>

In order to determine the level of compliance with these recommendations, we analyzed 110 *Cancer Research* articles that detect/measure apoptosis, published between August 15, 2010 and February 15, 2011, and 120 similar research articles published in *Cell Death & Disease* between January 1, 2010 and September 2011. In 21 of the *Cancer Research* and 15 of the *Cell Death & Disease* articles, apoptosis was determined by the authors for different treatments or in different settings using a different combination of apoptosis techniques each time, thus leading the total number of apoptotic determinations (entries) to 137 (*Cancer Research*) and 136 (*Cell Death & Disease*) (see Table 1 and Table 2). The results clearly show that in only 60 of the 137

entries (43.8%) for *Cancer Research* and 96 of the 136 entries (70.58%) for *Cell Death & Disease*, the authors used at least two different methods for apoptosis detection. In addition, we determined that in 5 of the 137 (3.64%) entries from *Cancer Research* and in 34 of the 136 (25%) of the entries from *Cell Death & Disease* the authors use at least three methods for apoptosis detection (Figure 1). Moreover, it is important to emphasize that most, if not all of the apoptosis techniques used to detect apoptosis as single methods may, as shown by some reports, also detect necrosis or other cellular processes. As an example, DNA fragmentation measured by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) (26 of 137 from *Cancer Research*; 26 of 136 from *Cell Death & Disease*) or subG1 DNA content (30 of 137 from *Cancer Research*; 18 of 136 from *Cell Death & Disease*) or Annexin V alone, without PI/7AAD (16 of 137 from *Cancer Research*; 7 of 136 from *Cell Death & Disease*) and other assays can also detect necrosis.<sup>1–6</sup> In addition, caspases can be activated during cellular processes other than apoptosis.<sup>1</sup> Thus, more than one method for apoptosis detection should be used.

In order to investigate the proper use of the specific name for each method used, we analyzed the same entries described above. Our analysis shows similar results for the two journals. While for *Cell Death & Disease*, 83 from 136 entries (61.02%) use the name of the specific method used for apoptosis detection, among the 137 entries from *Cancer Research*, 87 (63.5%) use the name of the specific method used (Figure 1). These results certainly leave space for improvement.

In conclusion, these results clearly suggest the need for improvements and of adequate guidelines for authors, reviewers, and editors regarding the apoptosis (in particular) and cell death (in general) detection, and quantification methods.

<sup>1</sup>Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, MA, USA; <sup>2</sup>Department of Molecular and Cell Biology, Institute of Biochemistry of the Romanian Academy, Bucharest, Romania; <sup>3</sup>Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; <sup>4</sup>Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA

\*Corresponding authors: A Almasan, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. Tel: +1 216 444 9970; Fax: +1 216 445 6269; E-mail: almasaa@ccf.org

or R Khosravi-Far, Department of Pathology, Harvard Medical School and Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. Tel: +1 617 667 8526; Fax: +1 617 667 8812; E-mail: rkhosrav@bidmc.harvard.edu

<sup>5</sup>These authors contributed equally to this work.

**Table 1** Evaluation of the *Cancer Research* experimental articles measuring apoptosis, published between August 15, 2010 and February 15, 2011<sup>17–116</sup>


| 2009 NCCD recommendations                                               | % from 137 entries | Details/comments                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------------------------------------------------------------|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use the specific name of the apoptosis method (A)                       | 87/137 = 63.5%     | 36.5% of all entries use expressions such as '% apoptosis', '% apoptotic cells', 'relative apoptotic cells (fold change)', '% death' and others, instead of indicating the specific method                                                                                                                                                                                                                                                                              |
| At least two methods for apoptosis detection (B)                        | 60/137 = 43.8%     | Amongst 77/137 entries only one method is used: 26/79–caspase cleavage/activation; 3/79 only PARP cleavage; 31/79 DNA fragmentation/nuclear condensation; 15/79 TUNEL; 1/79 TUNEL and ELISA; 8/79 subG1; 2/79 subG1 and ELISA; 2/79 subG1 and Hoechst; 1/79 Hoechst; 1/79 Yo-Pro-1; 9/79 Annexin V only; 6/79 Annexin V with PI/7-AAD; 1/79 Citokeratin-18 cleavage; 1/79 only Trypan blue exclusion and clonogenic assay; 1/79 only Calcein/ethidium bromide staining. |
| <b>Methods</b>                                                          |                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Caspase activation/Caspase cleavage/ PARP cleavage (1)                  | 84/137 = 61.13%    | 11/84 PARP cleavage only (without examining caspase activation)                                                                                                                                                                                                                                                                                                                                                                                                         |
| DNA fragmentation/nuclear condensation (2)                              | 66/137 = 48.17%    | 30/66 subG1; 26/66 TUNEL; 7/66 ELISA-nucleosomal fragmentation/release; 9/66 Hoechst 33342/33258, DAPI, Yo-Pro-1 (condensed/ fragmented chromatin)                                                                                                                                                                                                                                                                                                                      |
| Plasma membrane integrity/PS exposure (3)                               | 42/137 = 30.65%    | 16/42 of entries examine Annexin V positive cells only (not combined with PI/7AAD)                                                                                                                                                                                                                                                                                                                                                                                      |
| Activation of pro-apoptotic Bcl-2 family members (4)                    | 1/137 = 0.7%       | 1/6 shows Bax accumulation in the mitochondria; other 5/137 show only total levels of the pro/ anti-apoptotic members                                                                                                                                                                                                                                                                                                                                                   |
| Mitochondrial potential/integrity, release of pro-apoptotic factors (5) | 6/137 = 4.38%      | 3/6 measure MMP and cyt c release together; 1/6 detect MMP only; 2/6 detect the Apo2.7 early apoptotic marker                                                                                                                                                                                                                                                                                                                                                           |
| ROS detection (6)                                                       | 4/137 = 2.92%      | 4/4 DCFDA measurement of ROS                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Other apoptotic features (blebbing/ floating cells etc) (7)             | 2/137 = 1.45%      | 2/2 counting of floating cells (not specific for apoptosis)                                                                                                                                                                                                                                                                                                                                                                                                             |
| No. of entries using methods (1) and (2)                                | 32/137 = 21.89%    | 15/30 subG1+activation/cleavage of caspases/ PARP (method 1); 10/30 TUNEL+method 1                                                                                                                                                                                                                                                                                                                                                                                      |
| No. of entries using methods (1) and (3)                                | 24/137 = 17.51%    | 21/24 Annexin V/PI(or 7-AAD)+method 1; 3/87 Annexin V only (without PI/7-AAD)+method 1                                                                                                                                                                                                                                                                                                                                                                                  |
| No. of entries using methods (2) and (3)                                | 6/137 = 4.38%      | 3/6 - subG1+Annexin V/with or without PI (or 7-AAD); 3/6 Hoechst/DAPI+Annexin V with/ without PI or 7-AAD                                                                                                                                                                                                                                                                                                                                                               |
| No. of entries using at least three of the considered methods           | 5/137 = 3.65%      | Combinations of methods used: 1+2+3; 1+3+5; 1+3+6; 2+4+5+6; 1+2+5+7                                                                                                                                                                                                                                                                                                                                                                                                     |

Abbreviations: AAD, 7-amino-actinomycin D; Cyt c, cytochrome c; DAPI, 4, 6-diamidino-2-phenylindole; DCFDA, dichlorofluorescein diacetate; MMP, mitochondrial membrane potential; PARP, poly(ADP ribose) polymerase 1; PI, propidium iodide; PS, phosphatidylserine; ROS, reactive oxygen species; TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling. Note: A higher number of articles were published in *Cancer Research* between August 15, 2010 and February 15, 2011; however, they measured other non-apoptotic cellular processes: non-apoptotic cell death and signaling, mitotic catastrophe, autophagy, proliferation, metastasis, and others<sup>117–162</sup>

**Table 2** Evaluation of the *Cell Death & Disease* experimental articles measuring apoptosis, published between January 1, 2010 and September, 2011<sup>163–282</sup>

| 2009 NCCD recommendations                                               | % from 136 entries | Details/comments                                                                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use the specific name of the apoptotic method (A)                       | 83/136 = 61.03%    | 38.97% of all entries use expressions such as '% apoptosis', '% apoptotic cells', 'relative apoptotic cells (fold change)', '% death' and others, instead of mentioning the specific method                                                                                                                                  |
| At least two methods for apoptosis detection (B)                        | 96/136 = 70.58%    | 40/136 entries use only one method for apoptosis detection: 14/40 caspases cleavage/activation; 1/40 only PARP cleavage detection; 12/40 DNA fragmentation/nuclear condensation (5/40 TUNEL; 3/40 subG1; 3/40 Hoechst; 1/40 nucleosomal fragmentation/release); 10/40 AnnexinV+/-PI/7AAD or To-Pro-3; 2/40–MMP; 1/40 PI only |
| <b>Methods</b>                                                          |                    |                                                                                                                                                                                                                                                                                                                              |
| Caspase activation/caspase cleavage/ PARP cleavage (1)                  | 94/136 = 69.11%    | 7/94–PARP cleavage detection only (without examining caspase activation/cleavage); 5/94 zVAD only (without caspase activation/cleavage evaluation)                                                                                                                                                                           |
| DNA fragmentation/nuclear condensation (2)                              | 71/136 = 52.20%    | 26/71 TUNEL; 18/71 subG1; 15/71 Hoechst; 7/71 nucleosomal fragmentation/release; 4/71 DNA ladder; 4/71 nuclear condensation/fragmentation (EM); 3/71 Acridine orange; 2/71 DAPI; 3/71 unspecified method (DNA fragmentation/condensation)                                                                                    |
| Plasma membrane integrity/PS exposure (3)                               | 57/136 = 41.91%    | 52/57 Annexin V+/-PI or 7AAD (7/57 use Annexin V only); 2/57 PI/Yo-Pro-1; 2/57 Annexin V/To-Pro-3; 1/57 PI only                                                                                                                                                                                                              |
| Activation of pro-apoptotic Bcl-2 family members (4)                    | 7/136 = 5.14%      | 7/7 measure Bax, Bak, or Bid activity, localization (Bax and Bak) or cleavage (Bid); other 14/137 entries determine only their total levels                                                                                                                                                                                  |
| Mitochondrial potential/integrity, release of pro-apoptotic factors (5) | 36/136 = 26.47%    | 21/36 Cyt c release from mitochondria; 19/36 MMP; 4/36 measure both Cyt c release and MMP; 3/36 measure both Cyt c and Smac release                                                                                                                                                                                          |
| ROS detection (6)                                                       | 14/136 = 10.29%    | DFCDA and DHE measurements of ROS                                                                                                                                                                                                                                                                                            |
| Other apoptotic features (blebbing/apoptotic bodies) (7)                | 5/136 = 3.67%      | 3/5 cell blebbing; 2/5 apoptotic bodies                                                                                                                                                                                                                                                                                      |
| No. of entries using methods (1) and (2)                                | 45/136 = 33.08%    | 19/45 TUNEL+activation/cleavage of caspases/ PARP (method 1); 10/45 subG1+method 1; 9/45 Hoechst+method 1                                                                                                                                                                                                                    |
| No. of entries using methods (1) and (3)                                | 32/136 = 23.52%    | 28/32 AnnexinV+PI, 7-AAD or To-Pro-3+method 1; 3/87 Annexin V only (without PI/7-AAD)+method 1; 1/32 PI/Yo-Pro-1+method 1                                                                                                                                                                                                    |
| No. of entries using methods (2) and (3)                                | 19/136 = 13.97%    | 7/19 subG1+Annexin V with/without PI/7-AAD; 6/87 TUNEL+Annexin V with/without PI /7-AAD                                                                                                                                                                                                                                      |
| No. of entries using at least three of the considered methods           | 34/136 = 25%       | Combinations of methods used: 5/34 (1+2+3+5; 1+2+5; 1+3+5); 3/5 (1+2+3; 1+4+5); 2/34 (1+2+7; 1+3+6; 1+3+5+6); 1/6 (1+2+6; 1+2+4; 1+5+6; 1+2+4+5; 1+3+5+6; 1+3+4+5; 1+2+4+5+6+7)                                                                                                                                              |

Abbreviations: AAD, 7-amino-actinomycin D; Cyt c, cytochrome c; DCFDA, dichlorofluorescein diacetate; DHE, dihydroethidium; EM, electron microscopy; MMP, mitochondrial membrane potential; PARP, poly(ADP ribose) polymerase 1; PI, propidium iodide; PS, phosphatidylserine; ROS, reactive oxygen species. Note: A higher number of articles were published in *Cell Death & Disease* between January 1, 2010 and September, 2011; however, they measured other non-apoptotic cellular processes: non-apoptotic cell death and cell signaling, mitotic catastrophe, autophagy, proliferation, metastasis, and others<sup>283–317</sup>



**Figure 1** Evaluation of the *Cancer Research* and *Cell Death & Disease* articles. (a) Percentage of entries using the specific name of the apoptosis method used (87 of 137 = 63.5% for *Cancer Research*; 83 of 136 = 61.03% for *Cell Death & Disease*), instead of using the general terms such as 'percent apoptosis'. (b) Percentage of entries using one, two (55 of 137 = 40.14% for *Cancer Research*; 62 of 136 = 45.58% for *Cell Death & Disease*), or at least three methods (5 of 137 = 3.65% for *Cancer Research*; 34 of 136 = 25% for *Cell Death & Disease*) for apoptosis detection/quantification

## Conflict of Interest

The authors declare no conflict of interest.

**Acknowledgements.** OB received a fellowship from the Lady TATA Memorial Trust, London, UK. This work was also supported by the National Institutes of Health grants CA127264 (to AA), CA105306, CA131664, and HL080192 (to RK).

- Kroemer G *et al.* *Cell Death Differ* 2009; **16**: 3–11.
- Galluzzi L *et al.* *Cell Death Differ* 2012; **19**: 107–120.
- Grasl-Kraupp B *et al.* *Hepatology* 1995; **21**: 1465–1466.
- Jaeschke H, Lemasters JJ. *Gastroenterology* 2003; **125**: 1246–1257.
- Qian L *et al.* *Pathol Int* 1995; **45**: 207–214.
- Vermes I *et al.* *J Immunol Methods* 1995; **184**: 39–51.
- Albesiano E *et al.* *Cancer Res* 2010; **70**: 6467–6476.
- Cai D *et al.* *Cancer Res* 2010; **70**: 6477–6485.
- Leung TH, Ngan HY. *Cancer Res* 2010; **70**: 6486–6496.
- Cheng Y *et al.* *Cancer Res* 2010; **70**: 6516–6526.
- Xu J *et al.* *Cancer Res* 2010; **70**: 6566–6576.
- Landriscina M *et al.* *Cancer Res* 2010; **70**: 6577–6586.
- Chen R *et al.* *Cancer Res* 2010; **70**: 6587–6597.
- Shao Y, Aplin AE. *Cancer Res* 2010; **70**: 6670–6681.
- Rizvi S *et al.* *Cancer Res* 2010; **70**: 6787–6796.
- Halilovic E *et al.* *Cancer Res* 2010; **70**: 6804–6814.
- Lee SO *et al.* *Cancer Res* 2010; **70**: 6824–6836.
- Hartley JA *et al.* *Cancer Res* 2010; **70**: 6849–6858.
- Brill E *et al.* *Cancer Res* 2010; **70**: 6891–6901.
- Sinnberg T *et al.* *Cancer Res* 2010; **70**: 6999–7009.
- Caruso JA, Hunt KK, Keyomarsi K. *Cancer Res* 2010; **70**: 7125–7136.
- Ibrahim N *et al.* *Cancer Res* 2010; **70**: 7155–7165.
- Zhang X *et al.* *Cancer Res* 2010; **70**: 7176–7186.
- Peterson QP *et al.* *Cancer Res* 2010; **70**: 7232–7241.
- Jiang J *et al.* *Cancer Res* 2010; **70**: 7242–7252.
- Mologni L *et al.* *Cancer Res* 2010; **70**: 7253–7263.
- Seo JH *et al.* *Cancer Res* 2010; **70**: 7325–7335.
- Hofbauer SW *et al.* *Cancer Res* 2010; **70**: 7336–7344.
- Geng D *et al.* *Cancer Res* 2010; **70**: 7442–7454.

- Herrmann A *et al.* *Cancer Res* 2010; **70**: 7455–7464.
- Doedens AL *et al.* *Cancer Res* 2010; **70**: 7465–7475.
- Buggins AG *et al.* *Cancer Res* 2010; **70**: 7523–7533.
- Kumar M *et al.* *Cancer Res* 2010; **70**: 7553–7561.
- Rossi EA *et al.* *Cancer Res* 2010; **70**: 7600–7609.
- Odri GA *et al.* *Cancer Res* 2010; **70**: 7610–7619.
- Cheng X *et al.* *Cancer Res* 2010; **70**: 7684–7689.
- Yang PM *et al.* *Cancer Res* 2010; **70**: 7699–7709.
- Jiang H *et al.* *Cancer Res* 2010; **70**: 7882–7893.
- Yang D *et al.* *Cancer Res* 2010; **70**: 7905–7917.
- McKenzie JA *et al.* *Cancer Res* 2010; **70**: 7927–7937.
- Hastak K, Alli E, Ford JM. *Cancer Res* 2010; **70**: 7970–7980.
- Kohmo S *et al.* *Cancer Res* 2010; **70**: 8025–8035.
- Elyakim E *et al.* *Cancer Res* 2010; **70**: 8077–8087.
- Dong Y *et al.* *Cancer Res* 2010; **70**: 8088–8096.
- Chiarini F *et al.* *Cancer Res* 2010; **70**: 8097–8107.
- Yang CH *et al.* *Cancer Res* 2010; **70**: 8108–8116.
- Cole AM *et al.* *Cancer Res* 2010; **70**: 8149–8158.
- Garcia-Barros M *et al.* *Cancer Res* 2010; **70**: 8179–8186.
- Omori E *et al.* *Cancer Res* 2010; **70**: 8417–8425.
- Hall CA *et al.* *Cancer Res* 2010; **70**: 8517–8525.
- Hong L *et al.* *Cancer Res* 2010; **70**: 8547–8557.
- Jäämaa S *et al.* *Cancer Res* 2010; **70**: 8630–8641.
- Pchejetski D *et al.* *Cancer Res* 2010; **70**: 8651–8661.
- Kunnumakkara AB *et al.* *Cancer Res* 2010; **70**: 8695–8705.
- Gopal YN *et al.* *Cancer Res* 2010; **70**: 8736–8747.
- Luoto KR *et al.* *Cancer Res* 2010; **70**: 8748–8759.
- Chock KL *et al.* *Cancer Res* 2010; **70**: 8782–8791.
- Chen Y *et al.* *Cancer Res* 2010; **70**: 8917–8926.
- Ghosh JC *et al.* *Cancer Res* 2010; **70**: 8988–8993.
- Shibata T *et al.* *Cancer Res* 2010; **70**: 9095–9105.
- Wahdan-Alaswad RS *et al.* *Cancer Res* 2010; **70**: 9106–9117.
- de Souza Rocha Simonini P *et al.* *Cancer Res* 2010; **70**: 9175–9184.
- Kapur V *et al.* *Cancer Res* 2010; **70**: 9265–9276.
- Zhao Y *et al.* *Cancer Res* 2010; **70**: 9287–9297.
- Ou DL *et al.* *Cancer Res* 2010; **70**: 9309–9318.
- Kuroda S *et al.* *Cancer Res* 2010; **70**: 9339–9348.
- Hochgräfe F *et al.* *Cancer Res* 2010; **70**: 9391–9401.

68. Kalashnikova EV *et al. Cancer Res* 2010; **70**: 9402–9412.
69. Darsigny M *et al. Cancer Res* 2010; **70**: 9423–9433.
70. Zhou X, Mürner K. *Cancer Res* 2010; **70**: 9434–9443.
71. Lin SL *et al. Cancer Res* 2010; **70**: 9473–9482.
72. Gruenbacher G *et al. Cancer Res* 2010; **70**: 9611–9620.
73. Fenouille N *et al. Cancer Res* 2010; **70**: 9659–9670.
74. Tront JS *et al. Cancer Res* 2010; **70**: 9671–9681.
75. Gurtner A *et al. Cancer Res* 2010; **70**: 9711–9720.
76. Brignole C *et al. Cancer Res* 2010; **70**: 9816–9826.
77. Guo Y *et al. Cancer Res* 2010; **70**: 9875–9885.
78. Zhang X *et al. Cancer Res* 2010; **70**: 9895–9904.
79. Bonnaud S *et al. Cancer Res* 2011; **71**: 9905–9915.
80. Yanagisawa K *et al. Cancer Res* 2010; **70**: 9949–9958.
81. Krishnamurthy S *et al. Cancer Res* 2010; **70**: 9969–9978.
82. Wang L *et al. Cancer Res* 2010; **70**: 10112–10120.
83. Okuyama H *et al. Cancer Res* 2010; **70**: 10213–10223.
84. Colombo R *et al. Cancer Res* 2010; **70**: 10255–10264.
85. Siddiqui-Jain A *et al. Cancer Res* 2010; **70**: 10288–10298.
86. Lin JJ *et al. Cancer Res* 2010; **70**: 10310–10320.
87. Woldemichael GM *et al. Cancer Res* 2011; **71**: 134–142.
88. Bagci-Onder T *et al. Cancer Res* 2011; **71**: 154–163.
89. Catena R *et al. Cancer Res* 2011; **71**: 164–174.
90. Lopez G *et al. Cancer Res* 2011; **71**: 185–196.
91. Li CM *et al. Cancer Res* 2011; **71**: 216–224.
92. Jiang Y *et al. Cancer Res* 2011; **71**: 234–244.
93. Indran IR *et al. Cancer Res* 2011; **71**: 266–276.
94. Wang Y *et al. Cancer Res* 2011; **71**: 371–382.
95. Chang WH *et al. Cancer Res* 2011; **71**: 383–392.
96. Iraci N *et al. Cancer Res* 2010; **71**: 404–412.
97. Anderson VE *et al. Cancer Res* 2011; **71**: 463–472.
98. Rérole AL *et al. Cancer Res* 2011; **71**: 484–495.
99. Song JH *et al. Cancer Res* 2011; **71**: 506–515.
100. Prasad S *et al. Cancer Res* 2011; **71**: 538–549.
101. Smith BH. *Cancer Res* 2011; **71**: 716–724.
102. Schiavoni G *et al. Cancer Res* 2011; **71**: 768–778.
103. Slupianek A *et al. Cancer Res* 2011; **71**: 842–851.
104. Saydam O *et al. Cancer Res* 2011; **71**: 852–861.
105. Su CH *et al. Cancer Res* 2011; **71**: 884–894.
106. Solier S, Pommier Y. *Cancer Res* 2011; **71**: 906–913.
107. Brooke GN *et al. Cancer Res* 2011; **71**: 914–924.
108. Wang X *et al. Cancer Res* 2011; **71**: 925–936.
109. Papageorgis P *et al. Cancer Res* 2011; **71**: 998–1008.
110. Van Schaeybroeck S *et al. Cancer Res* 2011; **71**: 1071–1080.
111. Mazumdar T *et al. Cancer Res* 2011; **71**: 1092–1102.
112. Chang HY *et al. Cancer Res* 2011; **71**: 1126–1134.
113. Nakazawa Y *et al. Cancer Res* 2011; **71**: 1146–1155.
114. Ji XD *et al. Cancer Res* 2011; **71**: 1156–1166.
115. Sen T *et al. Cancer Res* 2011; **71**: 1167–1176.
116. Hara K *et al. Cancer Res* 2011; **71**: 1229–1234.
117. Aleksic T *et al. Cancer Res* 2010; **70**: 6412–6419.
118. Xu T *et al. Cancer Res* 2010; **70**: 6420–6426.
119. Yasui H *et al. Cancer Res* 2010; **70**: 6427–6436.
120. Ladha J *et al. Cancer Res* 2010; **70**: 6437–6447.
121. Wang Y *et al. Cancer Res* 2010; **70**: 6448–6455.
122. Yang J *et al. Cancer Res* 2010; **70**: 6456–6466.
123. Cao L *et al. Cancer Res* 2010; **70**: 6497–6508.
124. Ratner E *et al. Cancer Res* 2010; **70**: 6509–6515.
125. Moore LE *et al. Cancer Res* 2010; **70**: 6527–6536.
126. Coenegrachts L *et al. Cancer Res* 2010; **70**: 6537–6547.
127. Mao FJ *et al. Cancer Res* 2010; **70**: 6548–6555.
128. Iida N *et al. Cancer Res* 2010; **70**: 6556–6565.
129. Kumar R *et al. Cancer Res* 2010; **70**: 6649–6658.
130. Balaguer F *et al. Cancer Res* 2010; **70**: 6609–6618.
131. Deka J *et al. Cancer Res* 2010; **70**: 6619–6628.
132. Metcalfe C *et al. Cancer Res* 2010; **70**: 6629–6638.
133. Ooi AT *et al. Cancer Res* 2010; **70**: 6639–6648.
134. Kumar R *et al. Cancer Res* 2010; **70**: 6598–6608.
135. Miki Y *et al. Cancer Res* 2010; **70**: 6659–6669.
136. Molina JR *et al. Cancer Res* 2010; **70**: 6697–6703.
137. Iadevaia S *et al. Cancer Res* 2010; **70**: 6704–6714.
138. Shin SY *et al. Cancer Res* 2010; **70**: 6715–6724.
139. Kerkar SP *et al. Cancer Res* 2010; **70**: 6725–6734.
140. Gupta S *et al. Cancer Res* 2010; **70**: 6735–6745.
141. Koike A *et al. Cancer Res* 2010; **70**: 6746–6756.
142. Rimmelé P *et al. Cancer Res* 2010; **70**: 6757–6766.
143. Takakura Y *et al. Cancer Res* 2010; **70**: 6767–6778.
144. Toniolo P *et al. Cancer Res* 2010; **70**: 6779–6786.
145. Schöllnberger H *et al. Cancer Res* 2010; **70**: 6797–6803.
146. Lingappa M *et al. Cancer Res* 2010; **70**: 6815–6823.
147. Terzuoli E *et al. Cancer Res* 2010; **70**: 6837–6848.
148. Hwang MK *et al. Cancer Res* 2010; **70**: 6859–6869.
149. Gilbert CA *et al. Cancer Res* 2010; **70**: 6870–6879.
150. Zhang YW *et al. Cancer Res* 2010; **70**: 6880–6890.
151. Atkinson JM *et al. Cancer Res* 2010; **70**: 6902–6912.
152. Muench P *et al. Cancer Res* 2010; **70**: 6913–6924.
153. Scarola M *et al. Cancer Res* 2010; **70**: 6925–6933.
154. Salhia B *et al. Cancer Res* 2010; **70**: 6934–6944.
155. Giannoni E *et al. Cancer Res* 2010; **70**: 6945–6956.
156. House CD *et al. Cancer Res* 2010; **70**: 6957–6967.
157. Si J *et al. Cancer Res* 2010; **70**: 6968–6977.
158. Lagarrigue F *et al. Cancer Res* 2010; **70**: 6978–6987.
159. Xu D *et al. Cancer Res* 2010; **70**: 6988–6998.
160. Sloan EK *et al. Cancer Res* 2010; **70**: 7042–7052.
161. Proulx ST *et al. Cancer Res* 2010; **70**: 7053–7062.
162. Endo-Munoz L *et al. Cancer Res* 2010; **70**: 7063–7072.
163. Allen-Petersen BL *et al. Cell Death Dis* 2010; **1**: e17.
164. Bunk EC *et al. Cell Death Dis* 2010; **1**: e15.
165. Cordeiro MF *et al. Cell Death Dis* 2010; **1**: e3.
166. Hervouet E *et al. Cell Death Dis* 2010; **1**: e8.
167. Ruela-de-Sousa RR *et al. Cell Death Dis* 2010; **1**: e19.
168. Wirawan E *et al. Cell Death Dis* 2010; **1**: e18.
169. Yacoubian TA *et al. Cell Death Dis* 2010; **1**: e2.
170. Brandt B *et al. Cell Death Dis* 2010; **1**: e23.
171. Ch'ng J-H *et al. Cell Death Dis* 2010; **1**: e26.
172. McKeller MR *et al. Cell Death Dis* 2010; **1**: e21.
173. Tomlinson V *et al. Cell Death Dis* 2010; **1**: e29.
174. Pasupuleti N *et al. Cell Death Dis* 2010; **1**: e31.
175. Deng L *et al. Cell Death Dis* 2010; **1**: e32.
176. Giampietri C *et al. Cell Death Dis* 2010; **1**: e38.
177. Gorvel L *et al. Cell Death Dis* 2010; **1**: e34.
178. Karaoz E *et al. Cell Death Dis* 2010; **1**: e36.
179. Karlberg M *et al. Cell Death Dis* 2010; **1**: e43.
180. Lei W-W *et al. Cell Death Dis* 2010; **1**: e44.
181. Meley D *et al. Cell Death Dis* 2010; **1**: e41.
182. Paoletti R *et al. Cell Death Dis* 2010; **1**: e45.
183. Placzek WJ *et al. Cell Death Dis* 2010; **1**: e40.
184. Wang G, Bieberich E. *Cell Death Dis* 2010; **1**: e46.
185. Flanagan L *et al. Cell Death Dis* 2010; **1**: e49.
186. Chan K-S *et al. Cell Death Dis* 2010; **1**: e57.
187. Fricker M *et al. Cell Death Dis* 2010; **1**: e59.
188. Knauer SK *et al. Cell Death Dis* 2010; **1**: e51.
189. Li Q *et al. Cell Death Dis* 2010; **1**: e56.
190. Ben Mosbah I *et al. Cell Death Dis* 2010; **1**: e52.
191. Ruiz A *et al. Cell Death Dis* 2010; **1**: e54.
192. Sayeed A *et al. Cell Death Dis* 2010; **1**: e53.
193. Tomiyama A *et al. Cell Death Dis* 2010; **1**: e60.
194. Wabnitz GH *et al. Cell Death Dis* 2010; **1**: e58.
195. Calandrella N *et al. Cell Death Dis* 2010; **1**: e62.
196. Dribben WH *et al. Cell Death Dis* 2010; **1**: e63.
197. Gonzalez-Mejia ME *et al. Cell Death Dis* 2010; **1**: e64.
198. Lam D *et al. Cell Death Dis* 2010; **1**: e66.
199. Perrone L *et al. Cell Death Dis* 2010; **1**: e65.
200. Upreti M *et al. Cell Death Dis* 2010; **1**: e67.
201. El-Fadili AK *et al. Cell Death Dis* 2010; **1**: e71.
202. Flourakis M *et al. Cell Death Dis* 2010; **1**: e75.
203. Heidari N *et al. Cell Death Dis* 2010; **1**: e76.
204. Janson V, Johansson A, Grankvist K. *Cell Death Dis* 2010; **1**: e78.
205. Jiang CC *et al. Cell Death Dis* 2010; **1**: e69.
206. Alajez NM *et al. Cell Death Dis* 2010; **1**: e85.
207. Cheng JPK *et al. Cell Death Dis* 2010; **1**: e82.
208. Marino ML *et al. Cell Death Dis* 2010; **1**: e87.
209. Matteucci C *et al. Cell Death Dis* 2010; **1**: e81.
210. Osato K *et al. Cell Death Dis* 2010; **1**: e84.
211. Reis CR *et al. Cell Death Dis* 2010; **1**: e83.
212. Schneider-Jakob S *et al. Cell Death Dis* 2010; **1**: e86.
213. Tejedo JR *et al. Cell Death Dis* 2010; **1**: e80.
214. Bose R *et al. Cell Death Dis* 2010; **1**: e92.
215. Karasawa T *et al. Cell Death Dis* 2010; **1**: e102.
216. Lian J *et al. Cell Death Dis* 2010; **1**: e94.
217. Sears D *et al. Cell Death Dis* 2010; **1**: e93.
218. Sikkink LA, Ramirez-Alvarado M. *Cell Death Dis* 2010; **1**: e98.
219. Sivananthan SN. *Cell Death Dis* 2010; **1**: e100.
220. Wang Y *et al. Cell Death Dis* 2010; **1**: e101.
221. Zhao C *et al. Cell Death Dis* 2010; **1**: e95.

222. Bhatnagar N *et al. Cell Death Dis* 2010; 1: e105.
223. Chu KME *et al. Cell Death Dis* 2010; 1: e106.
224. Gonzalez-Cano L *et al. Cell Death Dis* 2010; 1: e109.
225. Lee M-H *et al. Cell Death Dis* 2010; 1: e110.
226. McCoy F *et al. Cell Death Dis* 2010; 1: e108.
227. Benítez-Rangel E *et al. Cell Death Dis* 2011; 2: e113.
228. Degli Esposti D *et al. Cell Death Dis* 2011; 2: e111.
229. Ivanova S *et al. Cell Death Dis* 2011; 2: e116.
230. Mahmoudi S *et al. Cell Death Dis* 2011; 2: e114.
231. Witte I *et al. Cell Death Dis* 2011; 2: e112.
232. Zhu Q-y *et al. Cell Death Dis* 2011; 2: e117.
233. Kumar A *et al. Cell Death Dis* 2011; 2: e119.
234. Kurata M *et al. Cell Death Dis* 2011; 2: e118.
235. Lembo-Fazio L *et al. Cell Death Dis* 2011; 2: e122.
236. Liu Y *et al. Cell Death Dis* 2011; 2: e121.
237. Guzik K *et al. Cell Death Dis* 2011; 2: e131.
238. Kelk P *et al. Cell Death Dis* 2011; 2: e126.
239. Krzyzowska M *et al. Cell Death Dis* 2011; 2: e132.
240. Lablanche S *et al. Cell Death Dis* 2011; 2: e134.
241. Ling L-U *et al. Cell Death Dis* 2011; 2: e129.
242. Mühlethaler-Mottet A *et al. Cell Death Dis* 2011; 2: e125.
243. So EY *et al. Cell Death Dis* 2011; 2: e128.
244. Thellung S *et al. Cell Death Dis* 2011; 2: e138.
245. Miñano-Molina A *et al. Cell Death Dis* 2011; 2: e149.
246. Cheung HH *et al. Cell Death Dis* 2011; 2: e146.
247. Donadelli M *et al. Cell Death Dis* 2011; 2: e152.
248. Gao N *et al. Cell Death Dis* 2011; 2: e140.
249. Koster R *et al. Cell Death Dis* 2011; 2: e148.
250. Narducci MG *et al. Cell Death Dis* 2011; 2: e151.
251. Ahmed A *et al. Cell Death Dis* 2011; 2: e160.
252. Carmona-Gutiérrez D *et al. Cell Death Dis* 2011; 2: e161.
253. Liu H-L *et al. Cell Death Dis* 2011; 2: e159.
254. Mollinedo F *et al. Cell Death Dis* 2011; 2: e158.
255. Muglia C *et al. Cell Death Dis* 2011; 2: e163.
256. Quintavalle C *et al. Cell Death Dis* 2011; 2: e155.
257. Vaseva AV *et al. Cell Death Dis* 2011; 2: e156.
258. Zhang Y *et al. Cell Death Dis* 2011; 2: e153.
259. Ahmed Z *et al. Cell Death Dis* 2011; 2: e173.
260. Badmann A *et al. Cell Death Dis* 2011; 2: e171.
261. Barbone D *et al. Cell Death Dis* 2011; 2: e174.
262. Boehmerle W, Endres M. *Cell Death Dis* 2011; 2: e168.
263. Kuwahara Y *et al. Cell Death Dis* 2011; 2: e177.
264. Lim MP, Devi LA, Rozenfeld R. *Cell Death Dis* 2011; 2: e170.
265. Panzarini E, Inguscio V, Dini L. *Cell Death Dis* 2011; 2: e169.
266. Stevens JB *et al. Cell Death Dis* 2011; 2: e178.
267. Yivgi-Ohana N *et al. Cell Death Dis* 2011; 2: e166.
268. Kaur T *et al. Cell Death Dis* 2011; 2: e180.
269. Liu B *et al. Cell Death Dis* 2011; 2: e185.
270. Polier G *et al. Cell Death Dis* 2011; 2: e182.
271. Popov C *et al. Cell Death Dis* 2011; 2: e186.
272. Pujals A *et al. Cell Death Dis* 2011; 2: e184.
273. Zong D *et al. Cell Death Dis* 2011; 2: e181.
274. Coriat R *et al. Cell Death Dis* 2011; 2: e191.
275. Huelsenbeck J *et al. Cell Death Dis* 2011; 2: e190.
276. Lichtenberg M *et al. Cell Death Dis* 2011; 2: e196.
277. Osawa T, Davies D, Hartley JA. *Cell Death Dis* 2011; 2: e187.
278. Rauert H *et al. Cell Death Dis* 2011; 2: e194.
279. Thomas E *et al. Cell Death Dis* 2011; 2: e189.
280. Ai X *et al. Cell Death Dis* 2011; 2: e205.
281. Alameda JP *et al. Cell Death Dis* 2011; 2: e208.
282. Chauvier D *et al. Cell Death Dis* 2011; 2: e203.
283. Chi S *et al. Cell Death Dis* 2010; 1: e13.
284. Meltser V *et al. Cell Death Dis* 2010; 1: e20.
285. Morselli E *et al. Cell Death Dis* 2010; 1: e10.
286. Rodríguez J *et al. J Cell Death Dis* 2010; 1: e1.
287. Sassone J *et al. Cell Death Dis* 2010; 1: e7.
288. Silver N *et al. Cell Death Dis* 2010; 1: e14.
289. Straub WE *et al. Cell Death Dis* 2010; 1: e5.
290. Yuan M *et al. Cell Death Dis* 2010; 1: e16.
291. Almasieh M *et al. Cell Death Dis* 2010; 1: e27.
292. Francis KR, Wei L. *Cell Death Dis* 2010; 1: e22.
293. Rello-Varona S *et al. Cell Death Dis* 2010; 1: e25.
294. Sancho-Pelluz J *et al. Cell Death Dis* 2010; 1: e24.
295. Tenedini E *et al. Cell Death Dis* 2010; 1: e28.
296. Manning JA, Kumar S. *Cell Death Dis* 2010; 1: e35.
297. Nicolai J *et al. Cell Death Dis* 2010; 1: e33.
298. Scheiman J *et al. Cell Death Dis* 2010; 1: e42.
299. Fujita E *et al. Cell Death Dis* 2010; 1: e47.
300. Mitchell GC *et al. Cell Death Dis* 2010; 1: e50.
301. Romano S *et al. Cell Death Dis* 2010; 1: e55.
302. Diaz-Manera J *et al. Cell Death Dis* 2010; 1: e61.
303. Schneider B *et al. Cell Death Dis* 2010; 1: e68.
304. Barton CE *et al. Cell Death Dis* 2010; 1: e74.
305. Bennett HL *et al. Cell Death Dis* 2010; 1: e72.
306. Wu PC *et al. Cell Death Dis* 2010; 1: e70.
307. Yelamanchili SV *et al. Cell Death Dis* 2010; 1: e77.
308. Rigaud O *et al. Cell Death Dis* 2010; 1: e73.
309. Ciavardelli D *et al. Cell Death Dis* 2010; 1: e90.
310. Corona C *et al. Cell Death Dis* 2010; 1: e91.
311. Engel T *et al. Cell Death Dis* 2010; 1: e79.
312. Guardiola-Serrano F *et al. Cell Death Dis* 2010; 1: e88.
313. Tadokoro D *et al. Cell Death Dis* 2010; 1: e89.
314. Lanzillotta A *et al. Cell Death Dis* 2010; 1: e96.
315. Schmid R *et al. Cell Death Dis* 2010; 1: e97.
316. Jalmar O *et al. Cell Death Dis* 2010; 1: e103.
317. Wemeau M *et al. Cell Death Dis* 2010; 1: e104.



**Cell Death and Disease** is an open-access journal published by Nature Publishing Group. This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>